Silver sulfadiazine ointment — Competitive Intelligence Brief

Silver sulfadiazine ointment (Silver sulfadiazine ointment) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical antimicrobial agent. Area: Dermatology / Wound Care.

marketed Topical antimicrobial agent Bacterial cell wall and DNA; dihydropteroate synthase Dermatology / Wound Care Small molecule

Target snapshot

Silver sulfadiazine ointment (Silver sulfadiazine ointment) — SCARM Institute, Tabriz, Iran. Silver sulfadiazine releases silver ions that inhibit bacterial cell wall synthesis and disrupt microbial DNA, while sulfadiazine inhibits folate synthesis in bacteria.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Silver sulfadiazine ointment TARGET	Silver sulfadiazine ointment	SCARM Institute, Tabriz, Iran	marketed	Topical antimicrobial agent	Bacterial cell wall and DNA; dihydropteroate synthase
Manuka honey	Manuka honey	University of Zagreb	marketed	Natural product / Topical antimicrobial agent
CT Gel	CT Gel	Stiefel, a GSK Company	phase 3	Topical antimicrobial agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical antimicrobial agent class)

1. SCARM Institute, Tabriz, Iran · 1 drug in this class
2. Stiefel, a GSK Company · 1 drug in this class